Sharon Willis
Family · Minnetonka, MNNPI 1417236845
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 173 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 12.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,299, more than ten times the $15 reported in 2022. Among family clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 173 payments — averaging $18.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$394
- Otsuka America Pharmaceutical, Inc.$388
- Bayer$284
- Lundbeck LLC$257
- Lilly USA, LLC$227
- Novo Nordisk$201
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,09597%
- Education$993%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 24 | $394 |
| Otsuka America Pharmaceutical, Inc. | 19 | $388 |
| Bayer | 16 | $284 |
| Lundbeck LLC | 11 | $257 |
| Lilly USA, LLC | 14 | $227 |
| Novo Nordisk | 10 | $201 |
| AbbVie | 8 | $179 |
| Astellas Pharma US Inc | 4 | $166 |
| Kowa Pharmaceuticals America, Inc. | 17 | $141 |
| AstraZeneca | 7 | $134 |
| UCB, Inc. | 5 | $107 |
| GSK | 5 | $94 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $89 |
| Abbott | 4 | $84 |
| Idorsia Pharmaceuticals US Inc | 4 | $82 |
| Neurocrine Biosciences, Inc. | 4 | $80 |
| Ardelyx, Inc. | 4 | $80 |
| Boehringer Ingelheim | 3 | $51 |
| Scilex Pharmaceuticals Inc. | 2 | $44 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Novartis | 1 | $16 |
| Corcept Therapeutics | 1 | $15 |
| Neurelis, Inc. | 1 | $14 |
| Pfizer | 1 | $14 |
How this compares
$3,194 in reported general payments places this provider in the 95th percentile of 1,121 family providers in Minnesota.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 31 | $41,296 |
| JardianceEmpagliflozin | 49 | $35,218 |
| OzempicSemaglutide | 21 | $35,164 |
| MounjaroTirzepatide | 22 | $31,179 |
| LinzessLinaclotide | 32 | $27,723 |
| EliquisApixaban | 34 | $25,925 |
| RexultiBrexpiprazole | 15 | $23,924 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $18,388 |
| KerendiaFinerenone | 11 | $16,294 |
| GemtesaVibegron | 21 | $16,150 |
| FarxigaDapagliflozin Propanediol | 15 | $15,232 |
| MyrbetriqMirabegron | 13 | $12,803 |
| JanuviaSitagliptin Phosphate | 15 | $10,744 |
| TrulancePlecanatide | 13 | $7,279 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $3,467 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $227 | $72,47553 claims |
| Boehringer IngelheimJardiance | $51 | $35,21849 claims |
| Novo NordiskOzempic | $201 | $35,16421 claims |
| AbbVieLinzess, Synthroid | $179 | $28,96747 claims |
| PfizerEliquis | $14 | $25,92534 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $388 | $23,92415 claims |
| AstraZenecaFarxiga, Symbicort | $134 | $18,69830 claims |
| GSKTrelegy Ellipta | $94 | $18,38811 claims |
| BayerKerendia | $284 | $16,29411 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $394 | $16,15021 claims |
| Astellas Pharma US IncMyrbetriq | $166 | $12,80313 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $44 | $1,81618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,121 family providers in Minnesota.
Other family in Minnetonka
- Erin HewittMinnetonka$172K
- Alesya ShumkovMinnetonka$22K
- Laura ShepherdMinnetonka$13K
- June SansonMinnetonka$3K
- Julia GourdeMinneapolis$65K
- Robin DontaMinneapolis$60K
- Kristin WeberMinneapolis$35K
- Crista WenischBurnsville$30K
- Kathleen FredellMinneapolis$28K
- Christina RichardsonNorthfield$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.